BC Extra | Jun 4, 2019
Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
BC Week In Review | Jul 13, 2018
Company News

Bain acquires Royal DSM, Sinochem JV

The private equity business of Bain Capital LLC (Boston, Mass.) acquired the DSM Sinochem Pharmaceuticals Ltd. JV of Royal DSM N.V. (Euronext:DSM) and Sinochem Group (Beijing, China). Royal DSM will receive about €250 million ($291...
BC Week In Review | May 19, 2017
Financial News

Amyris raises $47M in first tranche of private placement

On May 11, biomanufacturing company Amyris Inc. (NASDAQ:AMRS) raised $47 million in the first tranche of a planned $95 million private placement from Royal DSM and other investors. Amyris Inc. (NASDAQ:AMRS), Emeryville, Calif. ...
BC Week In Review | Apr 18, 2016
Company News

OptiBiotix Health, Royal DSM deal

OptiBiotix and Royal DSM partnered to develop products to treat microbiome-associated diseases, including diabetes and obesity, using OptiBiotix’s OptiBiotic technology. OptiBiotixs said Royal DSM will have rights to new products in areas where the company...
BC Extra | Apr 14, 2016
Company News

Management tracks

CNS play Ovid Therapeutics Inc. (New York, N.Y.) hired Amit Rakhit as CMO and chief portfolio management officer. He was SVP and head of worldwide medical at Biogen Inc. (NASDAQ:BIIB). Orphan disease company Lumos Pharma...
BC Week In Review | Mar 17, 2014
Company News

Patheon, Royal DSM deal

Royal DSM and private equity firm JLL Partners completed the acquisition of CRO Patheon for $9.32 per share in cash, which the partners said gave the CRO an enterprise value of about $2 billion. Royal...
BC Week In Review | Nov 25, 2013
Company News

Patheon, Royal DSM deal

Royal DSM and private equity firm JLL Partners will acquire CRO Patheon for $9.32 per share in cash, which the partners said gives the CRO an enterprise value of about $2 billion. The price is...
BC Extra | Nov 20, 2013
Company News

DSM, private equity firm taking CRO Patheon private

Dutch chemicals company Royal DSM N.V. (Euronext:DSM) and private equity firm JLL Partners are teaming up to acquire CRO Patheon Inc. (TSX:PTI) for $9.32 per share in cash, which the partners said gives the CRO...
BC Week In Review | Oct 7, 2013
Company News

Cook Group, JHP Pharmaceuticals, Nanotherapeutics, Royal DSM, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded contracts to Cook's Cook Pharmica subsidiary, JHP, Nanotherapeutics and Royal DSM's DSM Pharmaceuticals Inc. division totaling $39.8 million. The companies will establish a fill and finishing...
BC Week In Review | May 27, 2013
Company News

J&J, Royal DSM deal

DSM said that on April 13, 2012, Percivia LLC terminated the PER.C6 biosimilars product development business as part of a restructuring of the company. Percivia, formerly Percivia PER.C6 Development Center, was established in 2006 to...
Items per page:
1 - 10 of 38
BC Extra | Jun 4, 2019
Politics & Policy

BIO appoints Levin chairman

BIO elected as its new chairman Jeremy Levin, who is chairman and CEO of Ovid Therapeutics Inc. (NASDAQ:OVID). He succeeds John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). The Biotechnology Innovation Organization elected Ted Love...
BC Week In Review | Jul 13, 2018
Company News

Bain acquires Royal DSM, Sinochem JV

The private equity business of Bain Capital LLC (Boston, Mass.) acquired the DSM Sinochem Pharmaceuticals Ltd. JV of Royal DSM N.V. (Euronext:DSM) and Sinochem Group (Beijing, China). Royal DSM will receive about €250 million ($291...
BC Week In Review | May 19, 2017
Financial News

Amyris raises $47M in first tranche of private placement

On May 11, biomanufacturing company Amyris Inc. (NASDAQ:AMRS) raised $47 million in the first tranche of a planned $95 million private placement from Royal DSM and other investors. Amyris Inc. (NASDAQ:AMRS), Emeryville, Calif. ...
BC Week In Review | Apr 18, 2016
Company News

OptiBiotix Health, Royal DSM deal

OptiBiotix and Royal DSM partnered to develop products to treat microbiome-associated diseases, including diabetes and obesity, using OptiBiotix’s OptiBiotic technology. OptiBiotixs said Royal DSM will have rights to new products in areas where the company...
BC Extra | Apr 14, 2016
Company News

Management tracks

CNS play Ovid Therapeutics Inc. (New York, N.Y.) hired Amit Rakhit as CMO and chief portfolio management officer. He was SVP and head of worldwide medical at Biogen Inc. (NASDAQ:BIIB). Orphan disease company Lumos Pharma...
BC Week In Review | Mar 17, 2014
Company News

Patheon, Royal DSM deal

Royal DSM and private equity firm JLL Partners completed the acquisition of CRO Patheon for $9.32 per share in cash, which the partners said gave the CRO an enterprise value of about $2 billion. Royal...
BC Week In Review | Nov 25, 2013
Company News

Patheon, Royal DSM deal

Royal DSM and private equity firm JLL Partners will acquire CRO Patheon for $9.32 per share in cash, which the partners said gives the CRO an enterprise value of about $2 billion. The price is...
BC Extra | Nov 20, 2013
Company News

DSM, private equity firm taking CRO Patheon private

Dutch chemicals company Royal DSM N.V. (Euronext:DSM) and private equity firm JLL Partners are teaming up to acquire CRO Patheon Inc. (TSX:PTI) for $9.32 per share in cash, which the partners said gives the CRO...
BC Week In Review | Oct 7, 2013
Company News

Cook Group, JHP Pharmaceuticals, Nanotherapeutics, Royal DSM, U.S. Department of Health and Human Services infectious news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded contracts to Cook's Cook Pharmica subsidiary, JHP, Nanotherapeutics and Royal DSM's DSM Pharmaceuticals Inc. division totaling $39.8 million. The companies will establish a fill and finishing...
BC Week In Review | May 27, 2013
Company News

J&J, Royal DSM deal

DSM said that on April 13, 2012, Percivia LLC terminated the PER.C6 biosimilars product development business as part of a restructuring of the company. Percivia, formerly Percivia PER.C6 Development Center, was established in 2006 to...
Items per page:
1 - 10 of 38